 |
 |
   |
Disease Targets
|
MacuSight is presently advancing sirolimus as a potential next-generation therapeutic for the treatment and prevention of wet age-related macular degeneration (wet AMD), as well as the treatment of diabetic macular edema (DME). |
   |
|
|
|
|
MacuSight is presently advancing sirolimus as a potential next-generation therapeutic for the treatment and prevention of wet age-related macular degeneration (wet AMD), as well as the treatment of diabetic macular edema (DME). |
|